← Leaderboards
Susan Little
University Of California San Diego
$46,798,571
Attributed
$51,175,973
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.2M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$74,305,006 · 16
By mechanism
P01$37,946,800 · 5
R24$23,116,312 · 1
R01$11,651,964 · 4
R34$703,794 · 1
P30$459,886 · 2
R21$426,250 · 1
Top collaborators
- Jeremy Sugarman5 shared
- Natasha Martin4 shared
- Keith Joseph Horvath3 shared
- Michael W Kalichman2 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Atsushi Miyanohara$2,817,616
- David Mitchell Smith$64,577,522
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsPersonsParticipantProgramsTransmission ProcessResourcesCommunitiesInfectionResearch PersonnelEpidemiologyLinkProspectiveEpidemicSpecimenEnsureInvestigationLaboratoriesClinical ResearchCohortAids PreventionAreaBiologicalBehavioralUniversities
Grant awards (75)
Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE$838,513
R01 · FY2025 · MH · contact PI
HIV Molecular Epidemiology (ME) Dashboard: Mapping HIV to Identify Prevention Gaps in Florida$812,427
R01 · FY2025 · AI · contact PI
SWG: EHE$343,762
P30 · FY2025 · AI · contact PI
Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE$960,731
R01 · FY2024 · MH · contact PI
Risks, Benefits, and Stakeholder Perspectives of Molecular Epidemiology for HIV Prevention (HIV-ME)$763,462
R01 · FY2024 · MH · contact PI
eSTEP: An integrated mHealth intervention to engage high-risk individuals along the full PrEP care continuum$230,997
R34 · FY2024 · MH
SWG: EHE$35,783
P30 · FY2024 · AI · contact PI
Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE$960,731
R01 · FY2023 · MH · contact PI
Risks, Benefits, and Stakeholder Perspectives of Molecular Epidemiology for HIV Prevention (HIV-ME)$773,476
R01 · FY2023 · MH · contact PI
Core-001 - COPE Core B$468,711
P01 · FY2023 · AI · contact PI
eSTEP: An integrated mHealth intervention to engage high-risk individuals along the full PrEP care continuum$230,818
R34 · FY2023 · MH
SWG: EHE$80,341
P30 · FY2023 · AI · contact PI
Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE$986,875
R01 · FY2022 · MH · contact PI
Risks, Benefits, and Stakeholder Perspectives of Molecular Epidemiology for HIV Prevention (HIV-ME)$792,335
R01 · FY2022 · MH · contact PI
Core-001 - COPE Core B$331,765
P01 · FY2022 · AI · contact PI
eSTEP: An integrated mHealth intervention to engage high-risk individuals along the full PrEP care continuum$241,979
R34 · FY2022 · MH
Primary Infection Resource Consortium (PIRC)$3,380,278
R24 · FY2021 · AI · contact PI
Risks, Benefits, and Stakeholder Perspectives of Molecular Epidemiology for HIV Prevention (HIV-ME)$737,669
R01 · FY2021 · MH · contact PI
Core B: Clinical and Anatomic Pathology Core$405,689
P01 · FY2021 · AI · contact PI
Primary Infection Resource Consortium (PIRC)$3,420,278
R24 · FY2020 · AI · contact PI
Risks, Benefits, and Stakeholder Perspectives of Molecular Epidemiology for HIV Prevention (HIV-ME)$810,968
R01 · FY2020 · MH · contact PI
Core B: Clinical and Anatomic Pathology Core$233,707
P01 · FY2020 · AI · contact PI
Primary Infection Resource Consortium (PIRC)$3,394,228
R24 · FY2019 · AI · contact PI
Core B: Clinical and Anatomic Pathology Core$231,061
P01 · FY2019 · AI · contact PI
Primary Infection Resource Consortium (PIRC)$3,577,318
R24 · FY2018 · AI · contact PI
Efficacy of ART to Interrupt HIV Transmission Networks$610,872
R01 · FY2018 · MH · contact PI
Core B: Clinical and Anatomic Pathology Core$214,274
P01 · FY2018 · AI · contact PI
Primary Infection Resource Consortium (PIRC)$3,311,878
R24 · FY2017 · AI · contact PI
Efficacy of ART to Interrupt HIV Transmission Networks$616,017
R01 · FY2017 · MH · contact PI
Core B: Clinical and Anatomic Pathology Core$245,816
P01 · FY2017 · AI · contact PI
Primary Infection Resource Consortium (Pirc)$1,443,529
R24 · FY2016 · AI · contact PI
Efficacy of ART to Interrupt HIV Transmission Networks$627,377
R01 · FY2016 · MH · contact PI
Primary Infection Resource Consortium (Pirc)$178,318
R24 · FY2016 · AI · contact PI
Primary Infection Resource Consortium (Pirc)$1,378,392
R24 · FY2015 · AI · contact PI
Efficacy of ART to Interrupt HIV Transmission Networks$647,944
R01 · FY2015 · MH · contact PI
Characterizing Privacy Perceptions and Risks in HIV Molecular Epidemiology$232,500
R21 · FY2015 · AI · contact PI
Primary Infection Resource Consortium (Pirc)$1,601,209
R24 · FY2014 · AI · contact PI
Efficacy of ART to Interrupt HIV Transmission Networks$712,567
R01 · FY2014 · MH · contact PI
Characterizing Privacy Perceptions and Risks in HIV Molecular Epidemiology$193,750
R21 · FY2014 · AI · contact PI
Primary Infection Resource Consortium (Pirc)$1,430,884
R24 · FY2013 · AI · contact PI
Determinants of HIV Transmission$4,146,197
P01 · FY2012 · AI · contact PI
Clincial and Specimen Core$1,605,435
P01 · FY2012 · AI · contact PI
Administrative Core$917,129
P01 · FY2012 · AI · contact PI
Determinants of HIV Transmission$4,153,957
P01 · FY2011 · AI · contact PI
Clincial and Specimen Core$1,605,285
P01 · FY2011 · AI · contact PI
Administrative Core$919,649
P01 · FY2011 · AI · contact PI
Determinants of HIV Transmission$4,383,189
P01 · FY2010 · AI · contact PI
Determinants of HIV Transmission$2,113,918
P01 · FY2010 · AI · contact PI
Clincial and Specimen Core$1,690,365
P01 · FY2010 · AI · contact PI
Administrative Core$972,384
P01 · FY2010 · AI · contact PI
Determinants of HIV Transmission$4,112,421
P01 · FY2009 · AI · contact PI
Clincial and Specimen Core$1,588,845
P01 · FY2009 · AI · contact PI
Administrative Core$912,861
P01 · FY2009 · AI · contact PI
Determinants of HIV Transmission$165,779
P01 · FY2009 · AI · contact PI
Determinants of HIV Transmission$4,053,572
P01 · FY2008 · AI · contact PI
Clincial and Specimen Core$1,580,013
P01 · FY2008 · AI · contact PI
Administrative Core$894,778
P01 · FY2008 · AI · contact PI
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2002 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2002 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2002 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2002 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2002 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2002 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2002 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2002 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2001 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2001 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2001 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2001 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2000 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2000 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2000 · RR
VIRAL AND IMMUNE DYNAMICS IN ACUTE HIV INFECTION$0
M01 · FY2000 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2000 · RR
EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS$0
M01 · FY2000 · RR